nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Cyclosporine—focal segmental glomerulosclerosis	0.66	1	CiPCiCtD
Vemurafenib—ALB—focal segmental glomerulosclerosis	0.146	1	CbGaD
Vemurafenib—ABCC1—Cyclosporine—focal segmental glomerulosclerosis	0.0716	0.49	CbGbCtD
Vemurafenib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.0479	0.328	CbGbCtD
Vemurafenib—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0163	0.111	CbGbCtD
Vemurafenib—Keratosis—Cyclosporine—focal segmental glomerulosclerosis	0.0126	0.439	CcSEcCtD
Vemurafenib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0104	0.0708	CbGbCtD
Vemurafenib—Hyperkeratosis—Cyclosporine—focal segmental glomerulosclerosis	0.0021	0.0735	CcSEcCtD
Vemurafenib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.000988	0.0345	CcSEcCtD
Vemurafenib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.000957	0.0334	CcSEcCtD
Vemurafenib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.000899	0.0314	CcSEcCtD
Vemurafenib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.000779	0.0272	CcSEcCtD
Vemurafenib—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.000736	0.0257	CcSEcCtD
Vemurafenib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.000704	0.0246	CcSEcCtD
Vemurafenib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.000544	0.019	CcSEcCtD
Vemurafenib—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.000449	0.0157	CcSEcCtD
Vemurafenib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.0004	0.014	CcSEcCtD
Vemurafenib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000341	0.0119	CcSEcCtD
Vemurafenib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000336	0.0117	CcSEcCtD
Vemurafenib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000336	0.0117	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00033	0.0115	CcSEcCtD
Vemurafenib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000297	0.0104	CcSEcCtD
Vemurafenib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000274	0.00957	CcSEcCtD
Vemurafenib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000272	0.0095	CcSEcCtD
Vemurafenib—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000271	0.00946	CcSEcCtD
Vemurafenib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000267	0.00932	CcSEcCtD
Vemurafenib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000263	0.00918	CcSEcCtD
Vemurafenib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000257	0.00899	CcSEcCtD
Vemurafenib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000229	0.00801	CcSEcCtD
Vemurafenib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000224	0.00781	CcSEcCtD
Vemurafenib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000224	0.00781	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000222	0.00776	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000215	0.00749	CcSEcCtD
Vemurafenib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000213	0.00744	CcSEcCtD
Vemurafenib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00021	0.00735	CcSEcCtD
Vemurafenib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000208	0.00728	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000195	0.00682	CcSEcCtD
Vemurafenib—RAF1—Endothelins—TRPC6—focal segmental glomerulosclerosis	0.000194	0.01	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—PIAS1—focal segmental glomerulosclerosis	0.000188	0.00972	CbGpPWpGaD
Vemurafenib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000186	0.00651	CcSEcCtD
Vemurafenib—BRAF—Focal Adhesion—COL4A1—focal segmental glomerulosclerosis	0.000186	0.00965	CbGpPWpGaD
Vemurafenib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000185	0.00647	CcSEcCtD
Vemurafenib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000185	0.00646	CcSEcCtD
Vemurafenib—RAF1—Nanoparticle-mediated activation of receptor signaling—FN1—focal segmental glomerulosclerosis	0.000184	0.00954	CbGpPWpGaD
Vemurafenib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000183	0.00641	CcSEcCtD
Vemurafenib—ALB—Platelet degranulation—ACTN4—focal segmental glomerulosclerosis	0.00018	0.00929	CbGpPWpGaD
Vemurafenib—BRAF—Corticotropin-releasing hormone—GNAQ—focal segmental glomerulosclerosis	0.000173	0.00895	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—ACTN4—focal segmental glomerulosclerosis	0.000171	0.00885	CbGpPWpGaD
Vemurafenib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00017	0.00592	CcSEcCtD
Vemurafenib—RAF1—Endothelins—GNAQ—focal segmental glomerulosclerosis	0.000162	0.00838	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000158	0.00552	CcSEcCtD
Vemurafenib—RAF1—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	0.000157	0.00811	CbGpPWpGaD
Vemurafenib—RAF1—TSH signaling pathway—GNAQ—focal segmental glomerulosclerosis	0.000156	0.00808	CbGpPWpGaD
Vemurafenib—BRAF—B Cell Receptor Signaling Pathway—CD79A—focal segmental glomerulosclerosis	0.000156	0.00807	CbGpPWpGaD
Vemurafenib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000154	0.00537	CcSEcCtD
Vemurafenib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000152	0.0053	CcSEcCtD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	0.000148	0.00766	CbGpPWpGaD
Vemurafenib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000147	0.00513	CcSEcCtD
Vemurafenib—RAF1—Signaling by PDGF—COL4A4—focal segmental glomerulosclerosis	0.000145	0.00752	CbGpPWpGaD
Vemurafenib—RAF1—BCR signaling pathway—CD79A—focal segmental glomerulosclerosis	0.000145	0.0075	CbGpPWpGaD
Vemurafenib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000142	0.00495	CcSEcCtD
Vemurafenib—RAF1—Focal Adhesion—COL4A4—focal segmental glomerulosclerosis	0.00014	0.00726	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00014	0.00723	CbGpPWpGaD
Vemurafenib—RAF1—Stimuli-sensing channels—TRPC6—focal segmental glomerulosclerosis	0.00014	0.00722	CbGpPWpGaD
Vemurafenib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000136	0.00476	CcSEcCtD
Vemurafenib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000135	0.00472	CcSEcCtD
Vemurafenib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000135	0.00472	CcSEcCtD
Vemurafenib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000134	0.00469	CcSEcCtD
Vemurafenib—RAF1—Signaling by PDGF—COL4A1—focal segmental glomerulosclerosis	0.000133	0.00691	CbGpPWpGaD
Vemurafenib—ALB—Lipid and lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	0.000129	0.00669	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—COL4A1—focal segmental glomerulosclerosis	0.000129	0.00667	CbGpPWpGaD
Vemurafenib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000127	0.00445	CcSEcCtD
Vemurafenib—RAF1—Endothelins—EDN1—focal segmental glomerulosclerosis	0.000126	0.0065	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MYH10—focal segmental glomerulosclerosis	0.000124	0.00641	CbGpPWpGaD
Vemurafenib—RAF1—Corticotropin-releasing hormone—GNAQ—focal segmental glomerulosclerosis	0.00012	0.00619	CbGpPWpGaD
Vemurafenib—ALB—Lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	0.000119	0.00615	CbGpPWpGaD
Vemurafenib—ABCG2—HIF-2-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000115	0.00593	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—COL4A3—focal segmental glomerulosclerosis	0.000113	0.00584	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	0.000109	0.00563	CbGpPWpGaD
Vemurafenib—RAF1—B Cell Receptor Signaling Pathway—CD79A—focal segmental glomerulosclerosis	0.000108	0.00558	CbGpPWpGaD
Vemurafenib—ABCG2—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000106	0.00546	CbGpPWpGaD
Vemurafenib—CYP2D6—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.000104	0.00537	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—PIAS1—focal segmental glomerulosclerosis	0.000103	0.00533	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—EDN1—focal segmental glomerulosclerosis	9.98e-05	0.00516	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	9.25e-05	0.00479	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	9.23e-05	0.00477	CbGpPWpGaD
Vemurafenib—RAF1—AGE/RAGE pathway—NOS2—focal segmental glomerulosclerosis	9.17e-05	0.00475	CbGpPWpGaD
Vemurafenib—RAF1—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—focal segmental glomerulosclerosis	9.16e-05	0.00474	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—COL4A4—focal segmental glomerulosclerosis	9.16e-05	0.00474	CbGpPWpGaD
Vemurafenib—RAF1—Ion channel transport—TRPC6—focal segmental glomerulosclerosis	9.1e-05	0.00471	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MYH10—focal segmental glomerulosclerosis	8.83e-05	0.00457	CbGpPWpGaD
Vemurafenib—CYP1A2—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	8.8e-05	0.00455	CbGpPWpGaD
Vemurafenib—RAF1—Retinoblastoma (RB) in Cancer—PCNA—focal segmental glomerulosclerosis	8.75e-05	0.00453	CbGpPWpGaD
Vemurafenib—RAF1—TWEAK Signaling Pathway—MMP9—focal segmental glomerulosclerosis	8.49e-05	0.0044	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—COL4A1—focal segmental glomerulosclerosis	8.42e-05	0.00435	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—AGT—focal segmental glomerulosclerosis	8.28e-05	0.00429	CbGpPWpGaD
Vemurafenib—ABCG2—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	8e-05	0.00414	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	7.97e-05	0.00412	CbGpPWpGaD
Vemurafenib—ALB—Lipid and lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	7.89e-05	0.00408	CbGpPWpGaD
Vemurafenib—RAF1—AGE/RAGE pathway—MMP2—focal segmental glomerulosclerosis	7.87e-05	0.00407	CbGpPWpGaD
Vemurafenib—RAF1—Oncostatin M Signaling Pathway—SERPINE1—focal segmental glomerulosclerosis	7.82e-05	0.00405	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	7.7e-05	0.00398	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	7.69e-05	0.00398	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ACTN4—focal segmental glomerulosclerosis	7.63e-05	0.00395	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—PCNA—focal segmental glomerulosclerosis	7.53e-05	0.0039	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	7.26e-05	0.00376	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—COL4A3—focal segmental glomerulosclerosis	7.11e-05	0.00368	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	7.1e-05	0.00367	CbGpPWpGaD
Vemurafenib—BRAF—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	6.99e-05	0.00362	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—SPP1—focal segmental glomerulosclerosis	6.9e-05	0.00357	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MYH9—focal segmental glomerulosclerosis	6.78e-05	0.00351	CbGpPWpGaD
Vemurafenib—RAF1—Interleukin-11 Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	6.74e-05	0.00349	CbGpPWpGaD
Vemurafenib—ABCG2—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	6.74e-05	0.00349	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—COL4A4—focal segmental glomerulosclerosis	6.53e-05	0.00338	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—FN1—focal segmental glomerulosclerosis	6.4e-05	0.00331	CbGpPWpGaD
Vemurafenib—RAF1—IL-3 Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	6.19e-05	0.0032	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	6.07e-05	0.00314	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—COL4A1—focal segmental glomerulosclerosis	6.01e-05	0.00311	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—SPP1—focal segmental glomerulosclerosis	5.96e-05	0.00308	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	5.94e-05	0.00307	CbGpPWpGaD
Vemurafenib—RAF1—AGE/RAGE pathway—MMP9—focal segmental glomerulosclerosis	5.92e-05	0.00306	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	5.9e-05	0.00305	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—FN1—focal segmental glomerulosclerosis	5.76e-05	0.00298	CbGpPWpGaD
Vemurafenib—RAF1—Cardiac Hypertrophic Response—TGFB1—focal segmental glomerulosclerosis	5.64e-05	0.00292	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	5.55e-05	0.00287	CbGpPWpGaD
Vemurafenib—BRAF—Corticotropin-releasing hormone—TGFB1—focal segmental glomerulosclerosis	5.4e-05	0.0028	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—FN1—focal segmental glomerulosclerosis	5.33e-05	0.00276	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—SERPINE1—focal segmental glomerulosclerosis	5.33e-05	0.00276	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—PCNA—focal segmental glomerulosclerosis	5.32e-05	0.00275	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—TRPC6—focal segmental glomerulosclerosis	5.23e-05	0.00271	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—SERPINE1—focal segmental glomerulosclerosis	5.11e-05	0.00264	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	5.11e-05	0.00264	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—COL4A3—focal segmental glomerulosclerosis	5.07e-05	0.00263	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—SPP1—focal segmental glomerulosclerosis	4.94e-05	0.00256	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	4.86e-05	0.00252	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MYH9—focal segmental glomerulosclerosis	4.84e-05	0.0025	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—FN1—focal segmental glomerulosclerosis	4.84e-05	0.0025	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—SPP1—focal segmental glomerulosclerosis	4.77e-05	0.00247	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	4.71e-05	0.00243	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	4.67e-05	0.00241	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—FN1—focal segmental glomerulosclerosis	4.28e-05	0.00222	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MYH9—focal segmental glomerulosclerosis	4.27e-05	0.00221	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	4.16e-05	0.00215	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ACTN4—focal segmental glomerulosclerosis	4.11e-05	0.00212	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	4.08e-05	0.00211	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—focal segmental glomerulosclerosis	4.02e-05	0.00208	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—FN1—focal segmental glomerulosclerosis	3.98e-05	0.00206	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	3.91e-05	0.00202	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	3.82e-05	0.00198	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	3.8e-05	0.00197	CbGpPWpGaD
Vemurafenib—RAF1—Corticotropin-releasing hormone—TGFB1—focal segmental glomerulosclerosis	3.74e-05	0.00193	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TRPC6—focal segmental glomerulosclerosis	3.73e-05	0.00193	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TRPC6—focal segmental glomerulosclerosis	3.66e-05	0.00189	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	3.56e-05	0.00184	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	3.53e-05	0.00183	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.4e-05	0.00176	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	3.4e-05	0.00176	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TGFB1—focal segmental glomerulosclerosis	3.36e-05	0.00174	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIAS1—focal segmental glomerulosclerosis	3.36e-05	0.00174	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	3.34e-05	0.00173	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	3.3e-05	0.00171	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—MMP9—focal segmental glomerulosclerosis	3.22e-05	0.00167	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	3.19e-05	0.00165	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.17e-05	0.00164	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	3.14e-05	0.00163	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.14e-05	0.00163	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—GNAQ—focal segmental glomerulosclerosis	3.06e-05	0.00158	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3e-05	0.00155	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	2.94e-05	0.00152	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—ALB—focal segmental glomerulosclerosis	2.93e-05	0.00152	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	2.89e-05	0.00149	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	2.8e-05	0.00145	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.76e-05	0.00143	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	2.75e-05	0.00142	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MYH9—focal segmental glomerulosclerosis	2.49e-05	0.00129	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	2.49e-05	0.00129	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	2.45e-05	0.00127	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.44e-05	0.00126	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—LPL—focal segmental glomerulosclerosis	2.35e-05	0.00121	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	2.31e-05	0.00119	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	2.25e-05	0.00116	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP2—focal segmental glomerulosclerosis	2.2e-05	0.00114	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	2.17e-05	0.00112	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	2.14e-05	0.00111	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	2.1e-05	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	2.09e-05	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	2.08e-05	0.00108	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.08e-05	0.00107	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	2.03e-05	0.00105	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	2e-05	0.00103	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	1.97e-05	0.00102	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	1.9e-05	0.000983	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	1.85e-05	0.00096	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.85e-05	0.000956	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—FN1—focal segmental glomerulosclerosis	1.82e-05	0.000942	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS2—focal segmental glomerulosclerosis	1.8e-05	0.00093	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.79e-05	0.000928	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.78e-05	0.000923	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.78e-05	0.00092	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	1.76e-05	0.000909	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	1.71e-05	0.000882	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	1.69e-05	0.000873	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—focal segmental glomerulosclerosis	1.66e-05	0.000857	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	1.65e-05	0.000852	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.63e-05	0.000842	CbGpPWpGaD
Vemurafenib—BRAF—Disease—LPL—focal segmental glomerulosclerosis	1.61e-05	0.000834	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	1.61e-05	0.000831	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	1.58e-05	0.000818	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	1.57e-05	0.000814	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.52e-05	0.000784	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.51e-05	0.000783	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ALB—focal segmental glomerulosclerosis	1.51e-05	0.000782	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD79A—focal segmental glomerulosclerosis	1.51e-05	0.000781	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.5e-05	0.000776	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.37e-05	0.00071	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.36e-05	0.000706	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	1.36e-05	0.000705	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.33e-05	0.000691	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	1.33e-05	0.00069	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.31e-05	0.000677	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.3e-05	0.000671	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.29e-05	0.000669	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS2—focal segmental glomerulosclerosis	1.26e-05	0.000651	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.24e-05	0.000642	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.23e-05	0.000638	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.23e-05	0.000636	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40LG—focal segmental glomerulosclerosis	1.23e-05	0.000636	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	1.18e-05	0.000612	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	1.17e-05	0.000608	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.16e-05	0.000602	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.14e-05	0.00059	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.14e-05	0.000589	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.13e-05	0.000585	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.13e-05	0.000584	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.13e-05	0.000584	CbGpPWpGaD
Vemurafenib—RAF1—Disease—LPL—focal segmental glomerulosclerosis	1.11e-05	0.000577	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—LPL—focal segmental glomerulosclerosis	1.1e-05	0.000572	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.08e-05	0.00056	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.07e-05	0.000553	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SERPINE1—focal segmental glomerulosclerosis	1.06e-05	0.000548	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.04e-05	0.000537	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	9.98e-06	0.000516	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	9.79e-06	0.000507	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	9.74e-06	0.000504	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	9.68e-06	0.000501	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AGT—focal segmental glomerulosclerosis	9.65e-06	0.000499	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	9.65e-06	0.000499	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	9.56e-06	0.000495	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	9.49e-06	0.000491	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—LPL—focal segmental glomerulosclerosis	9.25e-06	0.000479	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FN1—focal segmental glomerulosclerosis	8.92e-06	0.000461	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS2—focal segmental glomerulosclerosis	8.7e-06	0.00045	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS2—focal segmental glomerulosclerosis	8.63e-06	0.000446	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	8.23e-06	0.000426	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	8.15e-06	0.000422	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	8.14e-06	0.000421	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	8.04e-06	0.000416	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AGT—focal segmental glomerulosclerosis	7.91e-06	0.00041	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	7.89e-06	0.000408	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	7.8e-06	0.000404	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	7.42e-06	0.000384	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	7.39e-06	0.000382	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SERPINE1—focal segmental glomerulosclerosis	7.33e-06	0.000379	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SERPINE1—focal segmental glomerulosclerosis	7.27e-06	0.000376	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	7.25e-06	0.000375	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	6.96e-06	0.00036	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	6.8e-06	0.000352	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	6.75e-06	0.000349	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—focal segmental glomerulosclerosis	6.69e-06	0.000346	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.68e-06	0.000346	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	6.68e-06	0.000345	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	6.17e-06	0.000319	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—focal segmental glomerulosclerosis	6.07e-06	0.000314	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	5.98e-06	0.00031	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	5.76e-06	0.000298	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.68e-06	0.000294	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.51e-06	0.000285	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	5.34e-06	0.000277	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	5.18e-06	0.000268	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	5.14e-06	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.13e-06	0.000266	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	5.07e-06	0.000262	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	5.02e-06	0.00026	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.68e-06	0.000242	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.67e-06	0.000242	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—focal segmental glomerulosclerosis	4.63e-06	0.000239	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—focal segmental glomerulosclerosis	4.59e-06	0.000237	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	4.44e-06	0.00023	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	4.3e-06	0.000222	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	4.15e-06	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.93e-06	0.000203	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	3.91e-06	0.000202	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.6e-06	0.000187	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	3.55e-06	0.000184	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	3.51e-06	0.000182	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.24e-06	0.000168	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	3.01e-06	0.000156	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	2.72e-06	0.000141	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	2.71e-06	0.00014	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	2.32e-06	0.00012	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	2.31e-06	0.000119	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	1.78e-06	9.21e-05	CbGpPWpGaD
